FindTrial
Sign In

Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent Studies

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07791199
Enrollment
2300
Registered
2026-08-27
Start date
2026-12-31
Completion date
2030-10-31
Last updated
2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis, Psoriatic Arthritis, Sjögren's Disease, Systemic Lupus Erythematosus

Keywords

SLE, SJD, SJS, PSO, PSA, POETYK, POETYK-1, POETYK-2, POETK-SJS, jPSA, Pediatric, Juvenile, Deucravacitinib, SOTYKTU

Brief summary

This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.

Interventions

DRUGDeucravacitinib

Specified dose on specified days

Sponsors

Bristol-Myers Squibb
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Participants must have completed qualifying parent study through the protocol required treatment period. Qualifying studies include IM011-246, IM011-247, IM011-1069, IM011-126, IM011-1128, and IM011-1071.

Exclusion criteria

* Participants must not have any disease or medical condition that, in the opinion of the physician, would make them unsuitable for this protocol, would interfere with the interpretation of their safety or considered unsuitable by the physician for any other reason. Other protocol-defined inclusion/

Design outcomes

Primary

MeasureTime frame
Number of participants treatedUp to approximately 28 days after last dose of deucravacitinib

Contacts

CONTACTBMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com855-907-3286
CONTACTFirst line of the email MUST contain NCT # and Site #.
STUDY_DIRECTORBristol-Myers Squibb

Bristol-Myers Squibb

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026